ERT

AAIPharma appoints Browne as director of analytical chemistry

Wednesday, December 5, 2012 11:02 AM

AAIPharma Services, a provider of pharmaceutical product development services, has appointed David Browne as the company's director of analytical chemistry for its Edison, N.J., laboratory.

More... »

Vertex, GSK partner on phase II all-oral study of VX-135, GSK2336805 for Hep C

Friday, November 2, 2012 11:23 AM

Vertex Pharmaceuticals, a global biotechnology company based in Cambridge, Mass., has entered into a non-exclusive agreement with GlaxoSmithKline (GSK) to conduct a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex's nucleotide analogue HCV polymerase inhibitor VX-135 and GSK's NS5A inhibitor GSK2336805.

More... »

SpringFire Laboratory Network adds ReproSource to affiliate laboratories

Friday, October 19, 2012 10:32 AM

SpringFire Laboratory Network, a network of independent, esoteric, high complexity laboratories, has added ReproSource Fertility Diagnostics, a Boston-based clinical laboratory and research organization that provides solutions for fertility testing and education, to its network of affiliate laboratories, which provides specialized testing services to clinical trial sponsors and CROs.

More... »

Eckert & Ziegler acquires Vitalea Science

Tuesday, September 11, 2012 11:25 AM

Germany-based Eckert & Ziegler Strahlen- und Medizintechnik, through its Californian subsidiary Eckert & Ziegler Isotope Products (EZIP), has agreed to purchase all stock and assets of Vitalea Science. Vitalea Science is a bioanalytical CRO that provides services to researchers and clinicians in drug development supported by validated Accelerator Mass Spectrometry (AMS) technologies.

More... »

ERT launches enhanced platform to streamline data collection, analysis and processing

Friday, September 7, 2012 11:57 AM

ERT, a global technology-driven provider of health outcomes services, has launched an enhanced clinical research workflow technology designed to streamline data collection, analysis and processing in clinical trials.

More... »

ERT introduces enhanced platform to streamline clinical trial data collection

Tuesday, August 28, 2012 12:31 PM

Philadelphia-based ERT, a global provider of health outcomes services, has launched an enhanced clinical research workflow technology designed to streamline data collection, analysis and processing in clinical trials. The new offering, which comprises the EXPERT3 workflow platform and MyStudyPortal3 reporting engine, can simultaneously process health outcomes data across cardiac safety, Clinical Outcome Assessment (COA)/ePRO and respiratory studies. The platform offers users a simple way to process multiple types of data accurately, leading to fewer errors in studies.

More... »

ERT granted patents on clinical trial participant compliance

Tuesday, July 17, 2012 02:42 PM

Philadelphia-based ERT, a global technology-driven provider of health outcomes services to sponsors and CROs, has received two additional patents from the U.S. Patent and Trademark Office (U.S. Patent No. 8,065,180 and U.S. Patent No. 8,145,519).  The patents are titled System for Clinical Trial Subject Compliance and were acquired by ERT as part of its recent acquisition of invivodata.

More... »

ERT acquires invivodata

Monday, July 9, 2012 01:38 PM

ERT, a global technology-driven provider of health outcomes services, has decided to acquire invivodata, a provider of electronic Patient Reported Outcomes (ePRO) solutions and consulting services, based in Pittsburgh, Penn.

More... »

Genstar Capital completes ERT acquisition

Thursday, July 5, 2012 09:12 AM

Genstar Capital, a private equity firm, has completed its acquisition of ERT, a global technology-driven provider of health outcomes, in a take-private transaction valued at approximately $400 million.

More... »

Vertex corrects, provides additional data on cystic fibrosis study

Wednesday, May 30, 2012 10:44 AM

Vertex Pharmaceuticals of Cambridge, Mass., has released a correction to the previously reported responder analysis, as well as additional data from, its recent interim analysis of an ongoing phase II combination study of VX-809 and Kalydeco (ivacaftor) that showed significant improvements in lung function (forced expiratory volume in one second, FEV1) among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.

More... »